Literature DB >> 7085075

Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses.

M D Tolpin, M L Clements, M M Levine, R E Black, A J Saah, W C Anthony, L Cisneros, R M Chanock, B R Murphy.   

Abstract

In a previous study, a seronegative child to whom attenuated A/Alaska/77-ts-1A2 virus was administered (37 degrees C shutoff temperature for plaque formation) shed virus with an altered temperature-sensitive (ts) phenotype (40 degrees C shutoff temperature) (Murphy et al., Ann. N.Y. Acad. Sci. 354:172-182, 1980; Tolpin et al., Virology 112:505-517, 1981). This ts+ virus (FV1319) was evaluated for its level of replication in hamsters and for its virulence for humans. In hamsters, FV1319 ts+ virus replicated to the same level in the nasal turbinates as that of which the A/Alaska/77 wild-type virus replicated, but its replication in the lungs was reduced 40-fold. In contrast, the A/Alaska/77-ts-1A2 reassortant achieved a titer in hamster nasal turbinates that was significantly lower (P less than 0.005) than those achieved by the wild-type and the FV1319 viruses; the A/Alaska/77-ts-1A2 reassortant was not recoverable from the lungs. In seronegative adult volunteers, the pattern of replication of the FV1319 virus was similar to that of the A/Alaska/77 wild-type virus. The illness induced by the FV1319 ts+ virus was also similar to that caused by the wild-type virus. In contrast, the A/Alaska/77-ts-1A2 reassortant was satisfactorily attenuated in adult volunteers. These results suggest that attenuation of the A/Alaska/77-ts-1A2 reassortant virus in humans is a function of the ts phenotype: loss of this phenotype restored virulence. The ability of the A/Alaska/77-ts-1A2 reassortant to lose its ts phenotype and regain virulence during growth in a permissive host limits the usefulness of the ts-1A2 reassortants as vaccine viruses for humans.

Entities:  

Mesh:

Year:  1982        PMID: 7085075      PMCID: PMC351277          DOI: 10.1128/iai.36.2.645-650.1982

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Determination of influenzavirus neuraminidase inhibition titres.

Authors:  D D Richman; B R Murphy; W L Cline; D W Alling
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

2.  Virulence of temperature-sensitive mutants of foot-and-mouth disease virus.

Authors:  J S MacKenzie
Journal:  Arch Virol       Date:  1975       Impact factor: 2.574

3.  Temperature-sensitive mutants of influenza A virus. XIV. Production and evaluation of influenza A/Georgia/74-ts-1[E] recombinant viruses in human adults.

Authors:  D D Richman; B R Murphy; R B Belshe; H M Rusten; R M Chanock; N R Blacklow; T A Parrino; F B Rose; M M Levine; E Caplan
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

4.  Demonstration of a non-temperature-sensitive growth-restricting mutation in a ts mutant of influenza A virus: implications for live virus vaccine development.

Authors:  D D Richman; B R Murphy; R M Chanock
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

5.  Relationship between neurovirulence and temperature sensitivity of an attenuated western equine encephalitis virus.

Authors:  B Simizu; N Takayama
Journal:  Arch Gesamte Virusforsch       Date:  1971

6.  Cold adapted variants of influenza A. II. Comparison of the genetic and biological properties of ts mutants and recombinants of the cold adapted A/AA/6/60 strain.

Authors:  S B Spring; H F Maassab; A P Kendal; B R Murphy; R M Chanock
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

7.  Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults.

Authors:  D D Richman; B R Murphy; R M Chanock; J M Gwaltney; R G Douglas; R F Betts; N R Blacklow; F B Rose; T A Parrino; M M Levine; E S Caplan
Journal:  J Infect Dis       Date:  1976-12       Impact factor: 5.226

8.  Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2).

Authors:  P F Wright; S H Sell; T Shinozaki; J Thompson; D T Karzon
Journal:  J Pediatr       Date:  1975-12       Impact factor: 4.406

9.  Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen.

Authors:  H W Kim; J O Arrobio; C D Brandt; R H Parrott; B R Murphy; D D Richman; R M Chanock
Journal:  Pediatr Res       Date:  1976-04       Impact factor: 3.756

10.  Temperature-sensitive mutants of influenza A virus: production and characterization of A/Victoria/3/75-ts-1[E] recombinants.

Authors:  B R Murphy; N T Hosier; S B Spring; S R Mostow; R M Chanock
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

View more
  8 in total

1.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

2.  Molecular characteristics and biological properties (genetic markers) of candidate strains for preparation of live influenza virus vaccines.

Authors:  Y Z Ghendon
Journal:  Bull World Health Organ       Date:  1984       Impact factor: 9.408

3.  Genetically engineered live attenuated influenza A virus vaccine candidates.

Authors:  N T Parkin; P Chiu; K Coelingh
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Nucleoprotein and membrane protein genes are associated with restriction of replication of influenza A/Mallard/NY/78 virus and its reassortants in squirrel monkey respiratory tract.

Authors:  S F Tian; A J Buckler-White; W T London; L J Reck; R M Chanock; B R Murphy
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

5.  Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.

Authors:  Bin Zhou; Victoria A Meliopoulos; Wei Wang; Xudong Lin; Karla M Stucker; Rebecca A Halpin; Timothy B Stockwell; Stacey Schultz-Cherry; David E Wentworth
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

6.  Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.

Authors:  R B Belshe; R A Karron; F K Newman; E L Anderson; S L Nugent; M Steinhoff; M L Clements; M H Wilson; S L Hall; E L Tierney
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

7.  Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.

Authors:  E K Subbarao; E J Park; C M Lawson; A Y Chen; B R Murphy
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

8.  Intragenic suppression of a deletion mutation of the nonstructural gene of an influenza A virus.

Authors:  J J Treanor; R Buja; B R Murphy
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.